Enterprise Value
93.6M
Cash
172.3M
Avg Qtr Burn
-22.99M
Short % of Float
33.82%
Insider Ownership
7.43%
Institutional Own.
77.18%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PRT811 (PRMT5 inhibitor) Details Glioblastoma, Cancer, primary central nervous system lymphomas | Phase 1 Data readout | |
PRT543 (PRMT5 inhibitor) Details Solid tumor/s, Myelodysplastic syndrome, Myelofibrosis, Cancer | Phase 1 Data readout | |
PRT1419 (MCL1 inhibitor) Details Myelodysplastic syndrome, Non-Hodgkin lymphoma, Acute myeloid leukemia, Multiple myeloma | Phase 1 Data readout | |
PRT2527 (CDK9 inhibitor) Details Myelodysplastic syndrome, Non-Hodgkin lymphoma, Acute myeloid leukemia, Multiple myeloma | Phase 1 Data readout | |
PRT3645 (CDK4/6 inhibitor) Details Glioblastoma, Head and neck cancer, Non-small cell lung carcinoma, Breast cancer | Phase 1 Data readout |